L. salivarius

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Research on Ligilactobacillus salivarius has most heavily focused on its probiotic-relevant phenotypes and mechanisms in the oropharyngeal–gastrointestinal tract, including stress tolerance (acid/bile), adhesion/colonization potential, antimicrobial activity (including bacteriocin production), antioxidant capacity, and immunomodulatory effects. A second major theme is microbiome modulation: multiple studies and reviews emphasize strain-dependent effects on gut community structure and metabolic outputs, increasingly investigated using multi-omics (genomics, transcriptomics, proteomics, metabolomics) to connect genetic potential with secreted factors and host responses. Applied work is also prominent in animal production (notably laying hens), where selected strains have been evaluated for impacts on performance and gut health markers (e.g., mucin expression and innate immune signaling). In parallel, translationally oriented studies have examined L. salivarius in inflammatory disease contexts (e.g., colitis models) and as an antagonist of pathogens such as Staphylococcus aureus, including biofilm-associated infections.

The strongest evidence supports that certain L. salivarius strains can exert measurable antimicrobial effects and can be protective in preclinical inflammatory models, while also influencing host immune and barrier-related readouts. For example, functional validation in mouse models indicates protective roles in chemically induced colitis and inflammatory arthritis, underscoring that enrichment of Lactobacillus in disease-associated microbiome signatures may reflect adaptive or protective responses rather than causality. Mechanistically, anti-pathogen activity is supported by large reductions in planktonic and biofilm S. aureus in vitro and by identification of candidate secreted proteins potentially contributing to bactericidal effects beyond simple acidification. Evidence also supports diet–microbe interactions: fermentable polysaccharides can promote growth and metabolite production by related lactobacilli, and a human intestine-derived polyguluronate-utilizing L. salivarius shows anti-colitis potential, suggesting a plausible synbiotic strategy (substrate plus responsive strain) that merits further validation.

Key gaps include limited strain-to-strain generalizability and a relative shortage of robust human clinical evidence compared with preclinical and in vitro findings. Manufacturing and commercialization constraints are also a major bottleneck: many strains with promising functionality reportedly fail to maintain viability through industrial production and stabilization, indicating a need for deeper work on stress physiology, preservation mechanisms, and process optimization linked to post-processing functional retention. Additional priorities include clarifying causal mechanisms (specific metabolites, secreted proteins, and host pathways), defining which disease contexts are most likely to benefit (and in which direction), and standardizing comparative frameworks (genotype–phenotype mapping, dosing, endpoints, and safety/AMR surveillance) to enable reproducible translation from omics and animal models to clinically meaningful outcomes.

1. What conditions has L. salivarius been studied for?

  • Inflammatory/autoimmune disease models: Evaluated in mouse models of colitis (dextran sodium sulfate-induced) and arthritis (collagen type II-induced).

  • Ulcerative colitis (preclinical): Studied as a polyguluronate (PG)-utilizing Lactobacillus species with anti-colitis effects in mice (with translational relevance proposed for humans).

  • Hyperlipidemia / cardiometabolic risk markers (human): Tested in healthy young individuals for effects on lipid profile, inflammatory markers, and insulin sensitivity (6-week supplementation; probiotic alone or synbiotic with FOS).

  • Halitosis (human): Tested as an oral probiotic (L. salivarius WB21) for reducing volatile sulfur compounds (H2S) vs tongue scraping and antimicrobial photodynamic therapy (aPDT).

  • Pathogen inhibition / anti-infective activity (lab/animal):

    • Staphylococcus aureus (including biofilm) killing in vitro via secreted factors and pH-dependent mechanisms.

    • Microbiota modulation in mice and pigs with L. salivarius UCC118 (bacteriocin Abp118-dependent effects on some taxa).

  • Animal production/gut health (poultry): Studied in laying hens (e.g., L. salivarius CML352; another abstract on SNK-6 is truncated but indicates similar endpoints).

  • Other areas mentioned but not fully detailed in provided text: Rosacea (gut–skin axis) and silver nanoparticle synthesis using a probiotic strain (abstracts truncated, so outcomes/clinical relevance cannot be assessed here).

2. Does it work in treating those conditions? Summarize the evidence.

  • Colitis and arthritis (preclinical): supportive evidence in animals

    • A meta-analysis across 17 disease types identified Lactobacillus (including L. salivarius) as commonly enriched in autoimmune diseases; importantly, functional testing showed protective roles for L. salivarius in DSS-colitis and collagen-induced arthritis mouse models. The authors note enrichment may reflect a protective/adaptive response rather than harm.

    • In a separate UC-focused mouse study, L. salivarius (human intestine-derived, PG-utilizing) was reported to have potent anti-colitis effects, supporting plausibility for human translation, but this remains preclinical.

  • Halitosis (human): not effective as tested

    • In a randomized clinical study (n=52), L. salivarius WB21 capsules for 14 days did not reduce halitosis compared with baseline (no significant difference; p=0.7530). In contrast, aPDT and tongue scraping produced immediate reductions in halitosis measures.

  • Lipids/inflammation in healthy people (human): promising but limited evidence

    • In a 6-week study (45 healthy young individuals), L. salivarius UBL S22 (alone or with FOS) was associated with improved lipid profile (reduced total cholesterol, LDL, triglycerides; increased HDL) versus placebo; effects on total cholesterol and LDL were more pronounced with synbiotic (FOS). The abstract also reports reductions in inflammatory markers (hs-CRP, IL-6, IL-1β, TNF-α), though the provided text is truncated before full details.

    • Limitations: small sample size, healthy population (not hyperlipidemic patients), short duration, and strain-specificity (UBL S22).

  • S. aureus inhibition (in vitro): strong laboratory effect, not clinical proof

    • L. salivarius caused an 8.6-log10 reduction in planktonic and 6.3-log10 reduction in biofilm S. aureus in vitro. Killing was partially pH-dependent and also involved secreted factors; proteomics identified candidate proteins (e.g., LysM-containing peptidoglycan-binding protein; peptidase M23B). This supports antimicrobial potential but does not establish efficacy in humans.

  • Poultry gut health/production: positive in hens (not directly generalizable to humans)

    • L. salivarius CML352 supplementation in late-phase laying hens improved markers of gut health (e.g., increased Muc-2, decreased MyD88, IFN-γ, TLR-4), reduced abdominal fat deposition, and improved egg quality.

  • Microbiota modulation (animal models): subtle, bacteriocin-dependent effects

    • In mice and pigs, L. salivarius UCC118 had no major phylum-level shifts in mice, but in pigs reduced Spirochaetes and altered some Firmicutes genera; effects were linked to bacteriocin Abp118 production (not seen with a bacteriocin-deficient mutant).

3. What health benefits does it have?

  • Antimicrobial activity

    • Multiple strains can produce bacteriocins with antagonistic activity (e.g., UCC118 produces Abp118).

    • In vitro, strong killing activity against S. aureus, including biofilms, with evidence for secreted antimicrobial proteins plus pH effects.

  • Immunomodulatory / anti-inflammatory potential

    • Protective effects in mouse models of colitis and arthritis suggest anti-inflammatory activity in vivo (preclinical).

    • In hens, supplementation decreased expression of inflammatory signaling markers (MyD88, IFN-γ, TLR-4) and increased mucosal barrier marker Muc-2 (animal evidence).

    • In healthy humans, supplementation with strain UBL S22 was associated with reductions in inflammatory markers (hs-CRP, IL-6, IL-1β, TNF-α reported in abstract, though full details are truncated).

  • Gut microbiota modulation

    • Reviews describe strong resistance/adhesion in the oropharyngeal–gastrointestinal tract and the ability to influence microbiota composition and metabolic profiling (general, strain-dependent).

    • Animal sequencing work shows subtle but measurable microbiota shifts that can be bacteriocin-dependent (UCC118).

  • Metabolic/cardiometabolic markers (human evidence, limited)

    • In healthy young individuals, 6-week supplementation improved lipid profile (TC, LDL, TG down; HDL up), with stronger effects when combined with FOS (synbiotic).

  • Antioxidant properties (general claim in review)

    • One review notes “outstanding antioxidant” properties across strains; however, specific clinical outcomes are not provided in the abstracts shown.

4. Does it have any downsides or side effects?

  • Human side effects: The provided abstracts do not report specific adverse events or safety signals. Absence of reported harms here is not proof of safety across all populations (e.g., immunocompromised individuals were not discussed).

  • Effectiveness is strain- and indication-dependent: For halitosis, L. salivarius WB21 showed no clinical benefit in the trial described, highlighting that not all strains work for all outcomes.

  • Manufacturing/stability limitations (practical downside): A manufacturing-focused review notes many L. salivarius strains are underused commercially because they may have poor tolerance to environmental stresses during production and stabilization, potentially reducing viability and consistency of products.

  • Theoretical microbiome risks: Because L. salivarius can alter microbiota (sometimes bacteriocin-dependent), unintended shifts are possible, but the animal data presented suggest changes are generally subtle and not clearly harmful.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report any pharmacogenomic findings (i.e., no evidence that specific human genetic variants predict benefit, harm, dosing needs, or side-effect risk from L. salivarius supplementation).

  • What is known from these abstracts: Effects appear to be strongly strain-dependent (e.g., UCC118 bacteriocin production changes microbiota effects; WB21 did not improve halitosis; UBL S22 affected lipids/inflammation), but this is not linked to host genetics in the provided material.

  • Key limitation: Without genotype-stratified human trials or mechanistic studies connecting host variants to response, no evidence-based pharmacogenomic recommendations can be made from these abstracts.

References

  1. UnderstandingLigilactobacillus salivariusfrom Probiotic Properties to Omics Technology: A Review
    Yong Yang, Xin Song, Guangqiang Wang, Yongjun Xia, Zhiqiang Xiong (2024)
  2. Ligilactobacillus salivarius functionalities, applications, and manufacturing challenges.
    M Guerrero Sanchez, S Passot, S Campoy, M Olivares, F Fonseca (2022) - Applied microbiology and biotechnology
  3. Autoimmune diseases exhibit shared alterations in the gut microbiota.
    Tianjiao Wang, Peter R Sternes, Xue-Kun Guo, Huiying Zhao, Congmin Xu, Huji Xu (2024) - Rheumatology (Oxford, England)
  4. Polyguluronate alleviates ulcerative colitis by targeting the gut commensal Lactobacillus murinus and its anti-inflammatory metabolites.
    Lin Pan, Mingfeng Ma, Yamin Wang, Wei Dai, Tianyu Fu, Lihao Wang, Qingsen Shang, Guangli Yu (2024) - International journal of biological macromolecules
  5. Lactobacillus salivariusCML352 Isolated from Chinese Local Breed Chicken Modulates the Gut Microbiota and Improves Intestinal Health and Egg Quality in Late-Phase Laying Hens
    Chang Xu, Fuxiao Wei, Xinyue Yang, Yuqing Feng, Dan Liu (2022)
  6. Effect of Lactobacillus salivarius SNK-6 on egg quality, intestinal morphology, and cecal microbial community of laying hens.
    Wei Liu, Jie Liu, Dapeng Li, Haixia Han, Huaxiang Yan, Yan Sun, Qiuxia Lei, Jie Wang, Yan Zhou, Dingguo Cao, Huimin Li, Fuwei Li (2024) - Poultry science
  7. Probiotic
    Abdelmushin Abdelgadir, Mohd Adnan, Mitesh Patel, Juhi Saxena, Mohammad Jahoor Alam, Mohammed Merae Alshahrani, Ritu Singh, Manojkumar Sachidanandan, Riadh Badraoui, Arif Jamal Siddiqui (2024) - Heliyon
  8. Probiotics suppress LL37 generated rosacea-like skin inflammation by modulating the TLR2/MyD88/NF-κB signaling pathway.
    Xinyue Qi, Yiran Xiao, Xinfeng Zhang, Zhenlin Zhu, Hongyan Zhang, Jing Wei, Zhixiang Zhao, Ji Li, Tingtao Chen (2024) - Food & function
  9. Antimicrobial activity of Lactobacillus salivarius and Lactobacillus fermentum against Staphylococcus aureus.
    Mi-Sun Kang, Hae-Soon Lim, Jong-Suk Oh, You-Jin Lim, Karin Wuertz-Kozak, Janette M Harro, Mark E Shirtliff, Yvonne Achermann (2017) - Pathogens and disease
  10. Effect of Lactobacillus salivarius bacteriocin Abp118 on the mouse and pig intestinal microbiota.
    Eliette Riboulet-Bisson, Mark H J Sturme, Ian B Jeffery, Michelle M O'Donnell, B Anne Neville, Brian M Forde, Marcus J Claesson, Hugh Harris, Gillian E Gardiner, Patrick G Casey, Peadar G Lawlor, Paul W O'Toole, R Paul Ross (2012) - PloS one
  11. Short term effect of antimicrobial photodynamic therapy and probiotic L. salivarius WB21 on halitosis: A controlled and randomized clinical trial.
    Pamella de Barros Motta, Marcela Leticia Leal Gonçalves, Juliana Maria Altavista Sagretti Gallo, Ana Paula Taboada Sobral, Lara Jansiski Motta, Marcia Pinto Alves Mayer, Dione Kawamoto, David Casimiro de Andrade, Elaine Marcílio Santos, Kristianne Porta Santos Fernandes, Raquel Agnelli Mesquita-Ferrari, Alessandro Melo Deana, Anna Carolina Ratto Tempestini Horliana, Sandra Kalil Bussadori (2024) - PloS one
  12. Effect of Probiotic Lactobacillus salivarius UBL S22 and Prebiotic Fructo-oligosaccharide on Serum Lipids, Inflammatory Markers, Insulin Sensitivity, and Gut Bacteria in Healthy Young Volunteers: A Randomized Controlled Single-Blind Pilot Study.
    Hemalatha Rajkumar, Manoj Kumar, Nilita Das, S Nishanth Kumar, Hanumanth R Challa, Ravinder Nagpal (2015) - Journal of cardiovascular pharmacology and therapeutics
  13. Effects of a Lactobacillus salivarius mixture on performance, intestinal health and serum lipids of broiler chickens.
    Parisa Shokryazdan, Mohammad Faseleh Jahromi, Juan Boo Liang, Kalavathy Ramasamy, Chin Chin Sieo, Yin Wan Ho (2017) - PloS one
  14. Multi-function screening of probiotics to improve oral health and evaluating their efficacy in a rat periodontitis model.
    Qingqing Nie, Xuchun Wan, Hua Tao, Qianqian Yang, Xueyang Zhao, Haixia Liu, Jun Hu, Yanan Luo, Ting Shu, Ran Geng, Zhijing Gu, Fengkai Fan, Zhi Liu (2023) - Frontiers in cellular and infection microbiology
  15. Candidate-Probiotic Lactobacilli and Their Postbiotics as Health-Benefit Promoters
    Lili Dobreva, Nikoleta Atanasova, Petar Donchev, Ekaterina Krumova, Radoslav Abrashev (2024)
  16. Effect of a Lactobacillus Salivarius Probiotic on a Double-Species Streptococcus Mutans and Candida Albicans Caries Biofilm.
    Wirginia Krzyściak, Dorota Kościelniak, Monika Papież, Palina Vyhouskaya, Katarzyna Zagórska-Świeży, Iwona Kołodziej, Beata Bystrowska, Anna Jurczak (2017) - Nutrients
  17. Lactobacillus salivarius alleviates inflammation via NF-κB signaling in ETEC K88-induced IPEC-J2 cells.
    Jiayun Qiao, Zeyang Sun, Dongmei Liang, Haihua Li (2020) - Journal of animal science and biotechnology
  18. Inhibitory effect of Lactobacillus salivarius on Streptococcus mutans biofilm formation.
    C-C Wu, C-T Lin, C-Y Wu, W-S Peng, M-J Lee, Y-C Tsai (2015) - Molecular oral microbiology
  19. Applications and safety considerations of Lactobacillus salivarius as a probiotic in animal and human health.
    B D Chaves, M M Brashears, K K Nightingale (2017) - Journal of applied microbiology
  20. Impact of the food grade heat-killed probiotic and postbiotic oral lozenges in oral hygiene.
    Chiao-Wen Lin, Yi-Tzu Chen, Hsieh-Hsun Ho, Yi-Wei Kuo, Wen-Yang Lin, Jui-Fen Chen, Jia-Hung Lin, Cheng-Ruei Liu, Chi-Huei Lin, Yao-Tsung Yeh, Ching-Wei Chen, Yu-Fen Huang, Chen-Hung Hsu, Pei-Shan Hsieh, Shun-Fa Yang (2022) - Aging


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!